Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) in Relapsed or Refractory Multiple Myeloma
NCT06223516Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Cytokine Release Syndrome Events at 56 days, Immune Cell-Associated Neurotoxicity Syndrome Events at 56 days and 4 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06223516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223516.